|03/15/17||Capnia Reports Fourth Quarter and Full Year 2016 Financial Results|
|REDWOOD CITY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016.
“During the fourth quarter, we embarked on a bold new strategic direction for our Company by signing a definitive agreement to merge with Essentialis, creating a dynamic new organization dedicated to dev... |
|03/08/17||Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company|
|Lead Clinical Asset Entering Phase II/III Development in 2017 for the Treatment of Prader-Willi Syndrome
Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones
REDWOOD CITY, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced that it has completed its previously-announced merger with privately-held Essentialis, Inc. effective M... |
|02/07/17||Capnia to Present at the 19th Annual BIO CEO & Investor Conference|
|REDWOOD CITY, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:00 AM ET at the Waldorf Astoria Hotel in New York City.
The presentation will be webcast live ... |
|12/27/16||Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company|
|Combined Company to Focus on Advancing Novel, Late-Stage Asset for the Treatment of Prader-Willi Syndrome, a Devastating, Orphan Disease
Enrollment in a Phase II/III Clinical Trial Expected to Begin in Second Half of 2017
$8 Million Concurrent Financing; Sufficient to Fund Development Plan Through Key Value-Creating Mi... |